The Zacks Analyst Blog Highlights Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Should l Buy PG?
Source: NASDAQ.COM
Featured Stocks: Zacks.com highlights stocks including Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy, and Canterbury Park, with insights on their recent performance and market challenges.
Market Analysis: The daily 'Ahead of Wall Street' article provides investors with economic updates and trading strategies, while Zacks emphasizes the importance of productivity and cost management for companies like PepsiCo and Procter & Gamble amidst various market pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PG
Wall Street analysts forecast PG stock price to rise
17 Analyst Rating
10 Buy
7 Hold
0 Sell
Moderate Buy
Current: 159.550
Low
150.00
Averages
164.50
High
180.00
Current: 159.550
Low
150.00
Averages
164.50
High
180.00
About PG
The Procter & Gamble Company is focused on providing branded consumer packaged goods to consumers across the world. The Company’s segments include Beauty, Grooming, Health Care, Fabric & Home Care and Baby, Feminine & Family Care. The Company’s products are sold in approximately 180 countries and territories primarily through mass merchandisers, e-commerce, including social commerce channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. It also sells direct to individual consumers. It has operations in approximately 70 countries. It offers products under brands, such as Head & Shoulders, Herbal Essences, Pantene, Rejoice, Olay, Old Spice, Safeguard, Secret, SK-II, Braun, Gillette, Venus, Crest, Oral-B, Ariel, Downy, Gain, Tide, Always, Always Discreet, Tampax, Bounty and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Shiba Inu Investment Prospects
- Price Volatility Analysis: As of February 16, Shiba Inu (SHIB) has surged an astonishing 97,000% over the past five years, yet it currently trades 93% below its peak from October 2021, indicating significant price volatility and uncertainty.
- Market Potential Assessment: Should Shiba Inu's market cap increase by a factor of 100, it would reach $380 billion, comparable to valuations of notable companies like Home Depot, Bank of America, and Procter & Gamble; however, the likelihood of achieving this is extremely low.
- Lack of Utility: Despite having a metaverse, decentralized exchange, and Layer-2 scaling solutions, Shiba Inu's lack of real-world applications puts it at a disadvantage in attracting users compared to cryptocurrencies with deeper developer networks.
- Diminishing Community Enthusiasm: The significant drop in Shiba Inu's price from its historical peak reflects a waning community enthusiasm, suggesting that investors should approach this asset, which relies on unpredictable hype cycles, with caution.
See More
Shiba Inu Faces Declining Community Support
- Declining Community Support: Shiba Inu's price has plummeted 93% from its October 2021 peak, indicating a waning community support that could lead to decreased investor confidence and negatively impact its future market performance.
- Limited Investment Return Potential: Despite a staggering 97,000% increase over the past five years, analysts believe the future investment return potential for Shiba Inu is extremely low due to a lack of real-world applications and increasing competition, prompting investors to consider safer options.
- Intensifying Market Competition: As more cryptocurrencies with practical applications emerge, Shiba Inu faces fierce competition from other digital assets, which could further erode its market share and affect its long-term growth potential.
- Poor Investment Recommendation: Analysts have noted that Shiba Inu is not included in the current top ten recommended stocks, suggesting a diminishing appeal as an investment choice, and advising investors to consider more promising assets for long-term gains.
See More
Nestlé Reports Strong Q4 Sales Growth, Plans Divestitures
- Sales Growth Exceeds Expectations: Nestlé's organic sales growth rate for Q4 reached 4%, surpassing analyst expectations of 3.55%, indicating strong market performance that boosts investor confidence.
- Future Growth Targets: The company aims for organic sales growth of 3% to 4% in 2026 while planning to improve its underlying trading operating profit margin, which stood at 16.1% in 2025, reflecting a positive outlook for future performance.
- Business Restructuring Plans: Nestlé intends to sell its remaining ice cream business to Froneri and has initiated the process to divest its water business, expected to be completed by 2027, which will help streamline operations and focus on core brands.
- Management Strategy Shift: Under the leadership of new CEO Philipp Navratil and Chairman Pablo Isla, Nestlé is accelerating its strategic transformation by concentrating on four core businesses, aiming to enhance operational efficiency and market performance.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Altria Group: Dividend Growth and Investment Opportunities
- Dividend Yield Advantage: Altria Group currently boasts a 6.3% dividend yield, and over the past five years, shareholders have achieved nearly 18% annualized returns through reinvested dividends, significantly outperforming the S&P 500's 13%, indicating its continued appeal among dividend investors.
- Market Performance Comparison: Since February 2021, Altria's total return has reached 128.6%, far exceeding the S&P 500's 85.8% and outperforming Coca-Cola and Procter & Gamble, showcasing its strong performance in the consumer goods sector despite challenges in industry innovation.
- Dependence on Tobacco Products: While Altria generates around 88% of its revenue from smokeable products, its competitor Philip Morris International has successfully derived 41.5% of its revenue from smoke-free products, highlighting Altria's lag in adapting to market changes, which could impact future growth potential.
- Future Growth Potential: Altria is expected to continue offsetting declining cigarette volumes through price increases, and if it can successfully launch smokeless products, it could significantly enhance its valuation, with a current price-to-earnings ratio of only 12 times, indicating its attractiveness as a long-term investment.
See More
Altria Group Raises Dividend for 56th Consecutive Year
- Dividend Growth: Altria Group has raised its dividend for 56 consecutive years, achieving Dividend King status with a current forward yield of 6.3%, which not only boosts investor confidence but also provides a stable cash flow for the company.
- Superior Investment Returns: Over the past five years, Altria has generated annualized returns nearing 18%, significantly outperforming the S&P 500's 13%, indicating that despite lagging in industry innovation, Altria can still deliver substantial returns to investors.
- Dependence on Tobacco Products: Although Altria has made slow progress in transitioning to smoke-free products, it still derives around 88% of its revenue from combustible products; however, successful future launches of smoke-free products could significantly enhance the company's valuation and market performance.
- Acquisition Potential: To bolster its smokeless product line, Altria may consider acquiring smaller competitors like Turning Point Brands, which could not only enhance earnings growth but also drive valuation expansion, as Altria currently trades at a forward P/E of just 12 times, well below competitors' 22 times.
See More
Analysis of Shiba Inu Investment Prospects
- Price Volatility Analysis: As of February 16, Shiba Inu (SHIB) has surged an astonishing 97,000% over the past five years, yet it currently trades 93% below its peak from October 2021, indicating significant price volatility and uncertainty.
- Market Potential Assessment: Should Shiba Inu's market cap increase by a factor of 100, it would reach $380 billion, comparable to valuations of notable companies like Home Depot, Bank of America, and Procter & Gamble; however, the likelihood of achieving this is extremely low.
- Lack of Utility: Despite having a metaverse, decentralized exchange, and Layer-2 scaling solutions, Shiba Inu's lack of real-world applications puts it at a disadvantage in attracting users compared to cryptocurrencies with deeper developer networks.
- Diminishing Community Enthusiasm: The significant drop in Shiba Inu's price from its historical peak reflects a waning community enthusiasm, suggesting that investors should approach this asset, which relies on unpredictable hype cycles, with caution.
See More
Shiba Inu Faces Declining Community Support
- Declining Community Support: Shiba Inu's price has plummeted 93% from its October 2021 peak, indicating a waning community support that could lead to decreased investor confidence and negatively impact its future market performance.
- Limited Investment Return Potential: Despite a staggering 97,000% increase over the past five years, analysts believe the future investment return potential for Shiba Inu is extremely low due to a lack of real-world applications and increasing competition, prompting investors to consider safer options.
- Intensifying Market Competition: As more cryptocurrencies with practical applications emerge, Shiba Inu faces fierce competition from other digital assets, which could further erode its market share and affect its long-term growth potential.
- Poor Investment Recommendation: Analysts have noted that Shiba Inu is not included in the current top ten recommended stocks, suggesting a diminishing appeal as an investment choice, and advising investors to consider more promising assets for long-term gains.
See More
Nestlé Reports Strong Q4 Sales Growth, Plans Divestitures
- Sales Growth Exceeds Expectations: Nestlé's organic sales growth rate for Q4 reached 4%, surpassing analyst expectations of 3.55%, indicating strong market performance that boosts investor confidence.
- Future Growth Targets: The company aims for organic sales growth of 3% to 4% in 2026 while planning to improve its underlying trading operating profit margin, which stood at 16.1% in 2025, reflecting a positive outlook for future performance.
- Business Restructuring Plans: Nestlé intends to sell its remaining ice cream business to Froneri and has initiated the process to divest its water business, expected to be completed by 2027, which will help streamline operations and focus on core brands.
- Management Strategy Shift: Under the leadership of new CEO Philipp Navratil and Chairman Pablo Isla, Nestlé is accelerating its strategic transformation by concentrating on four core businesses, aiming to enhance operational efficiency and market performance.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Altria Group: Dividend Growth and Investment Opportunities
- Dividend Yield Advantage: Altria Group currently boasts a 6.3% dividend yield, and over the past five years, shareholders have achieved nearly 18% annualized returns through reinvested dividends, significantly outperforming the S&P 500's 13%, indicating its continued appeal among dividend investors.
- Market Performance Comparison: Since February 2021, Altria's total return has reached 128.6%, far exceeding the S&P 500's 85.8% and outperforming Coca-Cola and Procter & Gamble, showcasing its strong performance in the consumer goods sector despite challenges in industry innovation.
- Dependence on Tobacco Products: While Altria generates around 88% of its revenue from smokeable products, its competitor Philip Morris International has successfully derived 41.5% of its revenue from smoke-free products, highlighting Altria's lag in adapting to market changes, which could impact future growth potential.
- Future Growth Potential: Altria is expected to continue offsetting declining cigarette volumes through price increases, and if it can successfully launch smokeless products, it could significantly enhance its valuation, with a current price-to-earnings ratio of only 12 times, indicating its attractiveness as a long-term investment.
See More
Altria Group Raises Dividend for 56th Consecutive Year
- Dividend Growth: Altria Group has raised its dividend for 56 consecutive years, achieving Dividend King status with a current forward yield of 6.3%, which not only boosts investor confidence but also provides a stable cash flow for the company.
- Superior Investment Returns: Over the past five years, Altria has generated annualized returns nearing 18%, significantly outperforming the S&P 500's 13%, indicating that despite lagging in industry innovation, Altria can still deliver substantial returns to investors.
- Dependence on Tobacco Products: Although Altria has made slow progress in transitioning to smoke-free products, it still derives around 88% of its revenue from combustible products; however, successful future launches of smoke-free products could significantly enhance the company's valuation and market performance.
- Acquisition Potential: To bolster its smokeless product line, Altria may consider acquiring smaller competitors like Turning Point Brands, which could not only enhance earnings growth but also drive valuation expansion, as Altria currently trades at a forward P/E of just 12 times, well below competitors' 22 times.
See More
